¹ Compounded medications are prepared by state-licensed compounding pharmacies and are not FDA-approved products. Compounded medications are not reviewed by the FDA for safety, efficacy, or manufacturing quality. Compounded GLP-1 medications are not the same as, equivalent to, or interchangeable with brand-name medications. GLP-1 clinical services are not available in all 50 states. Currently, services are not available in Louisiana and Mississippi. Service availability is subject to change based on state regulations and clinician licensure

² Telehealth consultations are conducted by independently licensed physicians. Service availability varies by location based on physician licensure. Telehealth may not be appropriate for all patients, and in-person evaluation may be recommended in some cases. Prescriptions, if clinically appropriate, are determined solely by the treating physician. GLP-1 clinical services are not available in all states. Currently, services are not available in Louisiana and Mississippi. Service availability is subject to change based on state regulations and clinician licensure

References

¹ Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl 4):16–27. doi:10.1111/dom.15728.

² Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183.

³Hume Health Corp. Lean Mass Preservation in Members: An Internal Outcomes Analysis. 2024. Hume Health Internal Study. Analysis of 8,000 premium members engaging with Pro.f insights and weighing a minimum of 3x per week; lean mass loss measured as a percentage of total weight lost via bioelectrical impedance analysis. Methodology available on request: support@humehealth.com.

⁴ Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564. doi:10.1111/dom.14725.

⁵ Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB. Muscle matters: the effects of medically induced weight loss on skeletal muscle. Lancet Diabetes Endocrinol. 2024;12(11):785–787. doi:10.1016/S2213-8587(24)00272-9.

⁶ Ravussin E, Bogardus C. Skeletal muscle metabolism is a major determinant of resting energy expenditure. J Appl Physiol. 1989;66(3). PMID:2243122.